|
Current Tenants |
|
Founded in 2008, aisle411 is first to market with a product search service using retail product location information to help consumers save time and money. aisle411 provides comprehensive product information to consumers via an iPhone App and Android App. Headquartered in St. Louis, Missouri, this innovative market leader is positioned for rapid growth across retail locations in the U.S. and internationally.
|
APT Therapeutics, Inc
Ridong Chen, Ph.D.
President
|
APT Therapeutics™ is developing optimized human apyrases as safe, effective, and cost-competitive antiplatelet therapy for acute myocardial infarction, stroke and transplantation complications. The business strategy is to out-license or co-develop the drug candidates with pharma partners. The Company was incorporated in 2001 and is headquartered in St Louis, Missouri.
|
Auxagen, Inc.
www.auxagen.com
Shuan S. Huang, Ph.D.
President & Research Director
|
Auxagen, Inc. One of the major missions of Auxagen Inc. is to develop wound healing and anti-fibrotic agents based on TGF-β receptor antagonist technology and to provide patients with the very best wound healing and fibrosis treatments. At Auxagen, Inc., active research is being undertaken to develop commercial applications of the technologies. These applications will significantly advance the treatments of wounds and tissue fibrosis, both of which currently lack effective therapies.
|
|
BacterioScan Inc. is a development-stage company which has developed, patented, and clinically validated a unique electro-optic technology and instrument for rapidly detecting and quantifying bacterial infections in bodily fluids. The company is initially targeting the rapid screening of urine to detect Urinary Tract Infection (UTI), an illness that afflicts over 100 million patients annually, and is the most common bacterial infection in humans. The Company was founded in Israel, and has relocated to St Louis as it pursues commercialization and expansion of its product lines.
_________________________________________________________ |
|
BioGenerator is a privately funded, non-profit 501(c)(3) organization created to facilitate the formation of successful, sustainable bioscience companies in the St. Louis region. BioGenerator is an affiliate of BioSTL. BioGenerator's mission is to support economic development and job growth in the St. Louis region. To accomplish this, BioGenerator identifies promising technologies and services, and works with the researcher or entrepreneur to build a successful and sustainable company.
_________________________________________________________ |
|
BioSynthema develops receptor-targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Its technology is based on the combination of novel tissue-specific, receptor-targeted peptides, and chemically linked metal chelates to derive compounds that have radiodiagnostic imaging and radiotherapeutic applications. Its scientists collaborate with an international group of scientists and clinical researchers. BioSynthema is developing a series of radionuclide-linked peptide diagnostic and therapeutic pair products, each targeted to a specific form of cancer and tumor type. This diagnostic/therapeutic pair approach represents a major advance over existing oncology products because it will allow physicians to use an in vivo diagnostic imaging agent to select patients most likely to respond to a corresponding radiotherapeutic. BioSynthema, a subsidiary of Advanced Accelerator Applications SA (France), is headquartered in St. Louis.
_________________________________________________________ |
C2N Diagnostics, LLC
www.c2ndiagnostics.com
Joel Braunstein, M.D., MBA
Chief Executive Officer
Tim West, Ph.D.
VP Research & Development
|
C2N Diagnostics is commercializing a transformative, dynamic biomarker platform that has potential to enable the detection and treatment of Alzheimer’s disease (AD) and other central nervous system (CNS) disorders at their earliest stages. This proprietary platform is based upon measuring in vivo human metabolism of brain-derived biomolecules implicated in AD and other forms of neurodegeneration using stable isotope labeling kinetics (SILK) (e.g., SILK-Ab® Total/Isoforms Assays, SILK-sAPPa/b™, and SILK-ApoE™, among others). Scientific American called the C2N platform discovered at the Washington University School of Medicine as one of the 50 most important discoveries of 2006. The SILK platform is potentially an enabling technology for (i) smarter, faster, and cheaper CNS drug development; and (ii) a biochemical test of pre-clinical AD, disease progression, and treatment responsiveness. C2N leverages the SILK platform both internally and collaboratively as a biomarker research service for companies developing innovative treatment approaches to neurodegeneration, and as a tool for novel drug target and biomarker discovery.
_________________________________________________________ |
|
Cardialen™ is developing low-voltage implantable cardioverters to provide painless defibrillation for treatment of atrial and ventricular tachyarrhythmias. It uses low, energy pulsed unpinning therapy, licensed jointly from Washington University in St. Louis and Case Western Reserve University, to achieve pain-free defibrillation. Initial focus is on atrial fibrillation (AF) and atrial flutter (AFL), the most common cardiac arrhythmias worldwide. Low-energy atrial cardioverters will help address unmet clinical needs, deliver pain-free therapy, reduce risk of stroke, lower healthcare costs and offer significant business opportunities. Cardialen™ has initiated preclinical testing, established offices in St. Louis, MO, and commenced product development in Minneapolis-St. Paul, MN.
_________________________________________________________ |
|
EndoStim Inc is a venture backed, early stage medical device company, engaged in the field of neurostimulation to treat gastroesophageal reflux disease (GERD), and potentially Urinary Urge Incontinence. The Company’s mission is to design and develop a novel, programmable microstimulator that can be implanted endoscopically to treat GERD, Urge Incontinence as well as other sphincter related disorders. The company believes that this approach will, for the first time, allow gastrointestinal specialists to treat refractory gastrointestinal reflux disease, a difficult-to-treat disease affecting millions of patients worldwide and position it to capture a significant market share of current more invasive surgical treatments, potentially establishing a new “gold standard” for less invasive intervention.
_________________________________________________________ |
Galera Therapeutics, LLC
www.galeratx.com
Robert A. Beardsley, Ph.D.
Chairman & Chief Executive Officer
|
Galera Therapeutics, LLC is developing agents to treat both cancer and the serious side effects associated with current cancer therapies. Galera is initially developing one of the candidates - a dismutase mimetic - for the prevention of oral mucositis (OM), a condition that limits effective cancer treatment in many patients. For many cancer patients, OM is a serious treatment side effect with no real remedies other than terminating or reducing the anti-tumor regimen. Subsequently, Galera will develop this lead candidate for protection against the broader side effects of radiation therapy (RT), and as direct anti-tumor co-therapy with radiation and traditional chemotherapeutic drugs. Galera was formed in 2009 by former executives from Kereos Inc. – including the inventor of this novel drug class – all with extensive drug development and biotech start-up experience.
_________________________________________________________ |
|
Grove Instruments, Inc. is a medical device company developing the first FDA-approved noninvasive, painless and bloodless portable glucose meter. Grove has a pipeline of noninvasive products including the world’s first personal noninvasive glucose meter for use in the lifelong care of the 25 million Americans with diabetes (more than 230 million worldwide). Our patented devices eliminate the pain, high cost, and inconvenience of current blood-based meters. Grove’s revolutionary device promotes optimal glucose monitoring and diabetes management thus giving every person with diabetes the opportunity for the dramatic medical and economic benefits of good glycemic (diabetes) control.
_________________________________________________________ |
Kereos, Inc.
www.kereos.com
Phillip M. Buckler
Chief Operating Officer
|
Kereos, Inc. develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease earlier and more specifically than currently possible. The specificity and unique capabilities of Kereos' molecular imaging agents enable earlier and more definitive diagnosis of disease. Similarly, Kereos' targeted therapeutics seek out definitive disease biomarkers; making them potentially more effective and less toxic in treating disease. Kereos is at the forefront of bringing targeted molecular imaging and therapy to patients and is committed to developing its pipeline of products to address the unmet medical needs associated with America's top two killers.
_________________________________________________________ |
|
Lickenbrock Technologies is an independent research and development company that creates advanced image processing algorithms and associated software for customer companies and federal agencies in the medical and defense industries. Lickenbrock develops products for technologies and applications, such as, image processing for medical and defense, signal recovery, deconvolution, random signals, and advanced software algorithms for optics.
_________________________________________________________ |
Medros, Inc.
www.medrospharma.com
Thomas Baranski,MD, PhD
and Ross Cagan, PhD
Co-Founders
Robert Karr, M.D.
President & CEO |
Rational drug delivery is constrained by the fact that pre-clinical modeling is expensive, time- consuming, and only weakly predictive of clinical results. Medros was developed by two professors from Washington University School of Medicine to utilize proprietary, high-throughput, and validated Drosophila-based (Fruit Fly) disease models to screen for drug candidates. These proprietary models hold the promise of better safety and efficacy data than traditional pre-clinical modeling techniques and are quicker and less expensive. Medros is focused on cancer and diabetes, serious and widespread diseases that represent two of the largest unmet needs in the medical marketplace. The current focus of Medros is providing contract research services to companies involved in drug discovery.
_________________________________________________________ |
|
Mobius Therapeutics™ is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the refractive and corneal indications are awaiting approval by the Food and Drug Administration.
_________________________________________________________ |
|
MulticoreWare Inc is a Software and Systems Integration solutions company which provides heterogeneous multicore solutions for high performance computing applications using multicore and many core processors. MulticoreWare provides tools for creating and porting software to heterogenous and homogenous multicore environments, offer algorithms optimized for multicore environments and provide consulting services for its clients in their transition to multicore environments. MulticoreWare is currently working with applications in the Defense and Aerospace, Bioinformatics, Life Sciences, Imaging, Scientific Computing and Financial Services industries.
_________________________________________________________ |
Elaine Mardis, Ph.D.,
President |
OmicMed is set to transform Cancer Care by enabling individualized treatment plans for cancer patients based on comprehensive analysis to yield improved patient outcomes by sophisticated, timely and low cost genomic analysis and medical interpretation. Omic analysis and interpretation pipeline modeled after the pioneering cancer genomics experience at The Genome Institute at Washington University St. Louis. Omic’s Software pipeline offered as Software as a Service (SaaS) will interpret NGS data from cancer samples, detect mutations and provide a medical interpretation of therapeutic options as a service within patient treatment schedules.
_________________________________________________________
|
|
Orion® Genomics, the Second Genetics Code Company, develops epigenetic research tools and molecular diagnostic products to fulfill the promise of personalized medicine. Orion’s lead product is a simple blood-based test that is being developed to identify people at elevated risk for colorectal cancer. The company has active biomarker discovery programs in cancers of the bladder, breast, lung, ovaries and colon, and the company offers genomics services to the medical, agricultural and bio-fuels research communities.
_________________________________________________________ |
|
Pepex Biomedical, Inc. medical device company which specializes in developing, manufacturing, and marketing disposable, miniaturized electrochemical biosensors. The company’s platform technologies provide advanced sensor designs well suited as an electrochemical assay with a broad array of applications including the potential to measure many different enzymes associated with body metabolism. The company has two distinct platform technologies: 1) a small “All In One” glucose meter with a breakthrough companion biosensor for diabetics (lancet integrated with the sensor and chemistry analysis cell); 2) continuous trend monitoring capabilities for lactate and glucose where the biosensor is placed trans-dermally and telemeters a wireless signal to a small readout device. Pepex has a profoundly comprehensive patent estate which protects its technology worldwide.
_________________________________________________________ |
Right On Site
Administrative Solutions, LLC
Judy Ballard
President & Founder
|
Right On Site Administrative Solutions, LLC was founded to provide bookkeeping and administrative support to start-up companies in the life-science industry in St. Louis. The company has provided support to more than 24 start-up companies, assisting in the set up of bookkeeping, filing systems, human resource files, etc. The staff of Right On Site brings over 25 years of professional experience in office management. Their clientele includes both for profit and not-for profit companies and has included extensive accounts payable, accounts receivable, human resource and executive level assistance to management, as well as SBIR and STTR grant administration. Our mission is to support and assist newly formed organizations until they have the resources to hire personnel.
_________________________________________________________ |
|
SADAR is developing a core positioning technology. Activities include research and development, light manufacturing and assembly, sales and distribution of products and services in the geospatial field.
_________________________________________________________ |
|
TradeHarbor’s Voice Signature ServiceSM offering (VSS) uses voice biometrics in a Web service to enable trusted interactions by conveniently authenticating persons over the telephone, on the Web and on mobile devices – while producing an exceptional customer experience and a significant Return-on-Investment. TradeHarbor’s unique “signature” approach provides legally-binding remote signatures for telephone, mobile and online transactions. Initial target markets include insurance, healthcare and financial services (including credit card transactions, mobile payments, brokerage services, mortgage origination, etc.). TradeHarbor’s vision is for the VSS to become the global standard for consumer authentication over the telephone, on the Web and mobile devices.
_________________________________________________________ |
|
Traxxsson is developing proprietary molecular tests to diagnose cancer and psychiatric diseases. The cancer assays are targeted to detect cancers which currently cannot be found using blood tests and to minimize the need for invasive biopsies to confirm the presence of cancer in instances where cancer screening tests already exist. The tests also are projected to be important validation tools for the development of successful new drugs. These unique diagnostic and tracking assays will provide clear demonstrations of drug efficacy.
_________________________________________________________ |
|
Notable Graduate Companies |
|
Bright Technologies runs several websites including LocalDeal.com and Shopr.com. LocalDeal.com offers collective buying opportunities between Merchants and consumers. Consumers benefit by purchasing limited-time deals at amazing discounts and easily sharing the savings by referring others to sign up and/or purchase. Merchants benefit from gaining new customers and repeat business
_________________________________________________________
|
DNA Polymerase
Technology, Inc.
www.klentaq.com
Wayne Barnes, Ph.D.
President |
DNA Polymerase Technology is working to develop improved technology for detecting, analyzing and manipulating genes. Its core area of research is PCR, which is a method for amplifying targeted sequences of DNA. Their current product is Klentaq1, an enzyme that catalyzes PCR and is used in thousands of laboratories throughout the world. For more information on the company and its products, visit their website.
_________________________________________________________ |
|
Exegy manufactures an appliance - the Exegy Ticker Plant - that is sold to banks, money managers and hedge funds. The appliance processes real-time streaming data from the world’s busiest exchanges and stock markets with unmatched throughput and ultra low latency.
_________________________________________________________ |
Expo Technologies, LLC
(F.K.A. SpectrAlliance)
www.expoforpat.com
Susan L. Bragg, Ph.D.
Technical Director |
Expo Technologies is an industry leader in the implementation of process analytical solutions for the pharmaceutical manufacturing industry. Expo designs builds and implements spectroscopic instrumentation for pharmaceutical industrial process control. Its range of products is designed to analyze and monitor a process stream in real time. These instruments are used in a range of operations including powder blending, drying and reactor vessel cleaning. Expo’s process control software products, NovaPAC© and NovaMath© provide ease of use while maintaining the security required by the Food and Drug Administration. The software features connectivity to a wide range of analytical instruments and simultaneous connectivity to the pharmaceutical manufacturer’s plant wide infrastructure.
_________________________________________________________ |
|
NVIDIA® (AGEIA) GeForce GPUs are exclusive integrators of PhysX® technology (developed by AGEIA), the world’s most pervasive physics engine delivering dynamic 3D realism to more than 150 games and used by more than 25,000 developers worldwide. With PhysX® video, developers can incorporate effects that dramatically change the way games are played and on-screen stories unfold.
_________________________________________________________ |
|
Pulse Therapeutics, Inc. is a medical device company developing magnetism-based technology to safely and effectively destroy blood clots in the endovascular system for deep vein thrombosis (DVT) and neurological stroke. The company’s goal is to make its technology the standard of care for stroke and DVT given its unique ability to be safer, faster, better, and cheaper than competing products. The team behind the company consists of experienced scientist, clinicians, and business leaders with a proven track history in commercializing groundbreaking medical technologies.
_________________________________________________________ |
|
Singulex, Inc. pioneered technology that detects minute quantities of proteins in blood to provide early detection of diseases (cancer) and life threatening situations (“silent” heart attacks). The company’s pharmaceutical partners use the tests to develop new drugs more efficiently, to provide early identification of serious side-effects, and to monitor drug effectiveness.
_________________________________________________________ |
|
Somark is a tech company that is developing a patented ID system based on a RFID Bio-Ink Tattoo. When applied, the ink creates a unique ID that can be detected without line of sight. The technology will be initially applied to the livestock industry to help identify and track cattle. Somark’s goals are to 1) ensure a safe food supply and 2) prevent export trade loss from food animal disease scares, e.g. BSE (a.k.a. Mad Cow Disease).
_________________________________________________________ |
|
Stereotaxis has a comprehensive range of proprietary products and solutions for cardiac interventional medicine which are built around magnetic technology. Procedures are conducted from outside the procedure room avoiding the x-ray field in use. Products are designed to provide patients with enhanced outcomes, safety and access to important new therapies, while improving cath lab efficiencies and physician safety, comfort and ease of use over conventional interventional methods.
_________________________________________________________ |
|
VirRx, Inc. The primary mission of VirRx is to design, construct, and evaluate genetically-engineered adenovirus “vectors” for use as drugs to treat human cancer. In VirRx’s program, genetic alterations are made in virus Ad5 such that following injection of the virus vector into a tumor, the vector will infect the tumor cells and replicate in the cells causing tumor cell destruction until the entire tumor is destroyed. The vector replicates preferentially in tumor cells as compared to non-tumor cells, so toxic side-effects are expected to be minimal. VirRx and collaborator Introgen have selected a vector to advance to a Phase I clinical trial for cancer. The secondary mission of VirRx is to exploit its expertise in adenovirus technology to conduct contract research and development.
_________________________________________________________ |
|
|
yurbuds®has developed technology to digitally scan ears, enabling the sale of personally-sized earbuds, satisfying the market need for an earbud that stays in the ear, is comfortable for hours and provides clinically proven better sound quality. The company has been named by Forbes as the 9th Most Promising Company in America and began sales in September 2009. Since 2009 the Company has built a retail presence in hundreds of locations nationwide including Best Buy stores. yurbuds® has developed a growing patent portfolio including 5 patents that have been granted. The Company continues to expand its retail presence receiving press from Forbes, The Wall Street Journal, The New York Times, Inc. Magazine and Reuters among others.
_________________________________________________________
|
|
Zassi Medical Evolutions, Inc. is a medical device innovation company specializing in the development of patient-centric, breakthrough gastrointestinal products. To date the company has innovated and monetized two groundbreaking gastrointestinal technologies – the Zassi Continent Ostomy Port (via an intellectual property license) and the Zassi Bowel Management System (via a product line sale). We are currently developing a family of products that will restore continence to individuals with colostomies and free them from 24/7 dependence on an ostomy pouch. The company created e-Zassi, a system for evaluating the commercial potential of new medical devices and for identifying collaborators.
_________________________________________________________ |
|
ZyStor Therapeutics, Inc. is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from rare genetic disorders known as lysosomal storage diseases (LSDs). There are more than 40 known LSDs, each caused by a deficiency in a different lysosomal enzyme. ZyStor has developed a novel, proprietary technologythat improves the delivery of therapeutics that replaces the missing lysosomal enzyme in patients and has demonstrated that the technology provides several distinct advantages over other LSD therapeutics. Its lead LSD therapy is for the treatment of Pompe Disease.
_________________________________________________________ |
